Celldex ax­es two more pro­grams to cut costs fol­low­ing glem­bat­u­mum­ab fail­ure; Zio­pharm stock slides on halt­ed brain can­cer tri­al

→ New Jer­sey-based biotech Celldex $CLDX is cut­ting two pro­grams from its pipeline, hoard­ing re­sources af­ter the fail­ure of its lead breast can­cer drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.